Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD-Microbiome
NCT07421947Not yet recruiting
- Sponsor
- University of Zurich
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic fecal microbiota in type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD), sponsored by University of Zurich. Primary endpoint: Change from baseline to 6 months in gut microbiome composition. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
type 2 diabetes mellitus (T2DM)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07421947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421947.